PDMR Interest in Shares and Share Options

RNS Number : 3426T

ReNeuron Group plc

11 October 2017

 

 

11 October 2017

AIM: RENE

ReNeuron Group plc

Director/PDMR Interest in Shares and Share Options

ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that, on 9 October 2017, the following grants made on 11 September 2017 under the Company's Long Term Incentive Plan (LTIP) were deemed accepted by the relevant Persons Discharging Managerial Responsibilities (PDMRs).  Share option grants made to Directors on 11 September 2017, which were separately announced by RNS on 12 September 2017, were also deemed accepted by those Directors on 9 October 2017. Under the terms of the grants, 9 October 2017 was the final day by which grantees could decline the option granted to them on 11 September 2017.

Name	Title	Date of grant of LTIP share options	Date LTIP share options accepted	Number of LTIP share options granted & accepted	Total shares over which options are held	Percentage of issued shares under option
Randolph Corteling	Head of Research	11 Sept 17	9 Oct 17	3,000,000	12,604,041	0.40%
Sharon Grimster	VP Development & General Manager - Wales	11 Sept 17	9 Oct 17	5,750,000	19,658,334	0.62%
John Hawkins (i)	Financial Controller	11 Sept 17	9 Oct 17	400,000	1,600,000	0.05%
Julian Howell	Chief Medical Officer	11 Sept 17	9 Oct 17	5,566,667	21,474,243	0.68%
Shaun Stapleton	Head of Regulatory Affairs	11 Sept 17	9 Oct 17	4,533,333	17,461,363	0.55%
John Sinden	Chief Scientific Officer	11 Sept 17	9 Oct 17	2,983,333	21,599,743	0.68%

The LTIP awards are share options granted at nominal value and are subject to a three-year holding period, exercisable from the third anniversary of the award.  The options are exercisable subject to the achievement of the following performance conditions:

1)    When the first patient is administered with a ReNeuron cell therapy in an eighth clinical trial, one third of the options will vest.

2)    When the sixth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest.

3)    If the Total Shareholder Return (TSR) of the Company meets or exceeds that of the FTSE AIM Healthcare Index in any given three year period from the date of grant, one third of the options will vest.

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.

(i) The grant to Mr Hawkins was made under the Company's Employee Share Option Plan and is exercisable subject to achievement of performance conditions (1) and (2) above, with 50% of the options vesting in each case.

ENDS

ENQUIRIES:

ReNeuron	[phone]
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan	[phone]
Mark Court, Sophie Cowles, Stephanie Watson
Stifel Nicolaus Europe Limited	[phone]
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
Nplus1 Singer Advisory LLP	[phone]
Mark Taylor (Joint Broker)

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company has therapeutic candidates in clinical development for disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.   

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Randolph Corteling
2	Reason for the notification
a)	Position/status	Head of Research
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 3,000,000
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

 (Disclosure in relation to share options granted and accepted by Directors and PDMRs)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sharon Grimster
2	Reason for the notification
a)	Position/status	VP Development & General Manager - Wales
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 5,750,000
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	John Hawkins
2	Reason for the notification
a)	Position/status	Financial Controller
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 400,000
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Julian Howell
2	Reason for the notification
a)	Position/status	Chief Medical Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 5,566,667
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Shaun Stapleton
2	Reason for the notification
a)	Position/status	Head of Regulatory Affairs
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 4,533,333
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	John Sinden
2	Reason for the notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 2,983,333
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Olav Hellebo
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 9,766,667
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Michael Hunt
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 6,800,000
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	John Berriman
2	Reason for the notification
a)	Position/status	Non-Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 500,000
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Simon Cartmell
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 500,000
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Tim Corn
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 500,000
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Claudia D'Augusta
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 500,000
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Chris Evans
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 500,000
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Mike Owen
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00B0DZML60
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 1p 500,000
d)	Aggregated information	N/A
e)	Date of the transaction	Granted 11 September 2017; Deemed accepted 9 October 2017
f)	Place of the transaction	Outside a trading venue

 

END

 

 

DSHEAAEFFAPXFFF